Stock 2269 WUXI BIOLOGICS (CAYMAN) INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials WuXi Biologics (Cayman) Inc.

Equities

2269

KYG970081173

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
13.48 HKD +5.81% Intraday chart for WuXi Biologics (Cayman) Inc. +6.81% -54.46%
Apr. 01 Wuxi Biologics Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer CI
Mar. 27 WuXi Biologics' 2023 Profit Falls 23% Despite Revenue Jump MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 53,985 114,126 353,422 318,544 223,341 51,944 51,944 -
Enterprise Value (EV) 1 49,901 109,822 348,931 312,303 219,728 108,159 44,936 43,879
P/E ratio 91.7 x 116 x 216 x 97.9 x 52.3 x 34.9 x 13.8 x 10.8 x
Yield - - - - - - - -
Capitalization / Revenue 21.3 x 28.6 x 63 x 31 x 14.6 x 6.67 x 2.84 x 2.36 x
EV / Revenue 19.7 x 27.6 x 62.2 x 30.4 x 14.4 x 6.35 x 2.46 x 1.99 x
EV / EBITDA 46.1 x 65.7 x 142 x 68 x 32 x 15.5 x 7.01 x 5.56 x
EV / FCF -86.2 x -54.8 x -83.5 x -101 x -673 x 129 x 264 x 19.3 x
FCF Yield -1.16% -1.82% -1.2% -0.99% -0.15% 0.77% 0.38% 5.19%
Price to Book 6.75 x 8.93 x 17.2 x 10.3 x 6.37 x 2.9 x 1.17 x 1.04 x
Nbr of stocks (in thousands) 3,677,824 3,883,578 4,084,763 4,224,123 4,225,262 4,162,831 4,162,831 -
Reference price 2 14.68 29.39 86.52 75.41 52.86 12.48 12.48 12.48
Announcement Date 3/18/19 3/26/20 3/23/21 3/22/22 3/22/23 3/26/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 2,534 3,984 5,612 10,290 15,269 17,034 18,280 22,036
EBITDA 1 1,083 1,671 2,464 4,590 6,857 6,993 6,413 7,892
EBIT 1 871 1,156 2,008 3,327 4,609 4,253 4,904 6,125
Operating Margin 34.36% 29.02% 35.79% 32.33% 30.18% 24.97% 26.83% 27.79%
Earnings before Tax (EBT) 1 737.7 1,127 1,966 3,993 5,358 4,174 4,749 6,023
Net income 1 630.5 1,010 1,689 3,388 4,420 3,400 3,919 4,987
Net margin 24.88% 25.36% 30.09% 32.93% 28.95% 19.96% 21.44% 22.63%
EPS 2 0.1600 0.2533 0.4000 0.7700 1.010 0.7700 0.9044 1.154
Free Cash Flow 1 -579 -2,003 -4,178 -3,106 -326.7 373.9 170.5 2,276
FCF margin -22.84% -50.27% -74.44% -30.19% -2.14% 2.22% 0.93% 10.33%
FCF Conversion (EBITDA) - - - - - 6.3% 2.66% 28.83%
FCF Conversion (Net income) - - - - - 9.74% 4.35% 45.63%
Dividend per Share 2 - - - - - - - -
Announcement Date 3/18/19 3/26/20 3/23/21 3/22/22 3/22/23 3/26/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 1,944 3,668 4,407 5,883 7,206 8,062 8,492 8,542 8,016 10,047
EBITDA - - - - - - - - - -
EBIT 1 - - 1,773 1,553 2,484 2,054 2,434 1,819 2,108 2,583
Operating Margin - - 40.24% 26.4% 34.47% 25.47% 28.66% 21.29% 26.3% 25.71%
Earnings before Tax (EBT) 1 - 1,261 - - - 2,428 2,529 1,645 - -
Net income 1 - 952.8 - 1,546 - 1,885 2,267 1,133 - -
Net margin - 25.97% - 26.28% - 23.38% 26.69% 13.26% - -
EPS - - - - - - 0.5200 - - -
Dividend per Share - - - - - - - - - -
Announcement Date 9/21/20 3/23/21 8/23/21 3/22/22 8/17/22 3/22/23 8/23/23 3/26/24 - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - - -
Net Cash position 1 4,084 4,304 4,491 6,241 3,612 5,448 7,008 8,065
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -579 -2,003 -4,178 -3,106 -327 374 171 2,276
ROE (net income / shareholders' equity) 10.5% 11.6% 10.1% 12.8% 13.1% 9.02% 9.06% 10.4%
ROA (Net income/ Total Assets) 8.86% 8.93% 7.25% 9.28% 9.45% 6.41% 6.9% 8.2%
Assets 1 7,120 11,317 23,283 36,498 46,798 53,070 56,803 60,819
Book Value Per Share 2 2.170 3.290 5.030 7.300 8.290 9.270 10.70 12.00
Cash Flow per Share 2 0.1900 0.3000 0.4400 0.7700 1.270 1.410 1.580 1.760
Capex 1 1,341 3,211 6,025 6,508 5,868 5,552 5,306 4,589
Capex / Sales 52.89% 80.59% 107.35% 63.24% 38.43% 32.97% 29.03% 20.82%
Announcement Date 3/18/19 3/26/20 3/23/21 3/22/22 3/22/23 3/26/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for WuXi Biologics (Cayman) Inc.

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
12.48 CNY
Average target price
26.4 CNY
Spread / Average Target
+111.57%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
WUXI BIOLOGICS (CAYMAN) INC. Stock WuXi Biologics (Cayman) Inc.
-54.46% 7.17B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2269 Stock
  4. Financials WuXi Biologics (Cayman) Inc.